Rituximab Trumps Natalizumab in MS Relapse : vimarsana.com

Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.

Related Keywords

Colorado , United States , Rocky Mountain , Boston , Massachusetts , Pennsylvania , Roche Genentech , Johnr Corboy , Rituximab Rituxan , Zongqi Xia , University Of Colorado , University Of Pittsburgh , Mountain Ms Center , Novartis , National Institute Of Neurological Disorders , Medscape Medical , Medscape Medical News , National Institute , Neurological Disorders , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Biologic Therapy , Monoclonal Antibody , Etuximab , Ituximab , Multiple Sclerosis Treatment , Als Treatment , Reatment Of Multiple Sclerosis , Reatment Of Ms , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Healthcare Technology , Healt ,